Josh Gottheimer sold Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH)
Josh Gottheimer (D-NJ), a U.S. Representative, has disclosed 4 trades in Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH) since 2021, all sales, worth an estimated $32K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Josh Gottheimer sold $1,001 - $15,000 of Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH) on January 4, 2022. Since that trade, SYNH is up +0.00% against the S&P 500 up +61.93%, an outperformance of -61.93%.
Across these filings, Josh Gottheimer has been a net seller of SYNH. The most recent disclosed SYNH transaction shown was dated January 23, 2023. Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
Josh Gottheimer's SYNH trades vs the price
SYNH is up +0.00% since Josh Gottheimer sold on January 4, 2022, versus +61.93% for the S&P 500.
Performance since this trade
All Josh Gottheimer SYNH trades
| Traded | Type | Size | Return | Est. profit | |
|---|---|---|---|---|---|
| January 23, 2023 | SELL | $1,001 - $15,000 | N/A | — | |
| December 6, 2022 | SELL | $1,001 - $15,000 | N/A | — | |
| January 4, 2022 | SELL | $1,001 - $15,000 | N/A | — | |
| August 20, 2021 | SELL | $1,001 - $15,000 | N/A | — |
Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.
Josh Gottheimer & SYNH trading FAQ
Is it legal for Josh Gottheimer to trade Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Josh Gottheimer sell SYNH?
Josh Gottheimer disclosed a sale of $1,001 - $15,000 of Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH) on January 4, 2022, according to public STOCK Act filings.
How has SYNH performed since Josh Gottheimer's trade?
Since Josh Gottheimer sold SYNH on January 4, 2022, the stock is up +0.00%, versus +61.93% for the S&P 500 over the same period, an outperformance of -61.93%.
How many times has Josh Gottheimer traded SYNH?
Josh Gottheimer has disclosed 4 SYNH trades since 2021. Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional SYNH trades?
Quantellect tracks every disclosed congressional trade in Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 (SYNH) on the Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1 congressional trading page, which aggregates filings across all members of Congress.
Josh Gottheimer's SYNH tradesAll congressional filings for Syneos Health, Inc. - Class A (SYNH) [ST] F ILING S TATUS : New S UbHOLdING O F : Morgan Stanley - Select UMA Account # 1Josh Gottheimer's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.